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CROSS-TALK BETWEEN THE RAAS AND THE VITAMIN D-FGF23-
KLOTHO AXIS
Activation of the renin-angiotensin-aldosterone system (RAAS) plays a major role in the 
development and progression of renal function loss as well as its cardiovascular complications. 
In chronic renal disease, deregulations in mineral metabolism including the vitamin D-fibroblast 
growth factor 23 (FGF23)-klotho axis are common and adversely affect cardiorenal outcomes. 
Interestingly, recent studies have suggested cross-talk at various levels between the RAAS and 
the vitamin D-FGF23-klotho axis.1 
The general aim of this thesis was to translate the implications of the cross-talk between 
these two major pathways into its clinical consequences. We have addressed this aim using two 
approaches. First, we studied the impact of modulation of the RAAS and the vitamin D-FGF23-
klotho axis on the risk of developing albuminuria and on anti-albuminuric treatment in CKD. 
Second, we studied the clinical impact of novel clinical readouts and factors downstream of the 
cross-talk in renal transplantation. 
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SUMMARY
Part I – Clinical impact of targeting cross-talk: albuminuria and renoprotective 
treatment
In chapter 1 we analyzed the interaction of vitamin D status and sodium intake on the risk 
of developing albuminuria in a general population based cohort. In this study we found an 
inverse association of 25-hydroxyvitamin D
3 
(25[OH]D) with the risk of developing albuminuria. 
This association could be explained by modulation of the RAAS by vitamin D. Vitamin D 
receptor (VDR) activation suppresses prorenin gene expression2, thus inhibiting RAAS activity3. 
Conversely, low vitamin D levels, through excessive renin production and subsequently 
angiotensin II activation, may facilitate albuminuria and subsequently renal inflammation and 
fibrosis.4,5 Interestingly, in line with the proposed cross-talk, the association between 25(OH)D 
and incident increased albuminuria was modified by sodium intake, an established modulator 
of the RAAS. Individuals with high sodium intake and low 25(OH)D levels had the highest risk to 
develop micro-albuminuria. A potential explanation could be that high sodium intake increases 
renal angiotensin-converting enzyme (ACE) activity.6,7 Increased renal ACE activity due to high 
sodium intake in combination with increased renin production as a consequence of low vitamin 
D levels may be additive factors promoting the development and progression of albuminuria. 
Alternatively, the interaction between vitamin D status and albuminuria by sodium intake could 
also be driven by pro-inflammatory and pro-fibrotic pathways, since both vitamin D deficiency8-11 
and high sodium intake12-14 have been linked to increased renal inflammation and fibrosis. To 
substantiate this observational association, prospective intervention in sodium status would be 
warranted. 
We performed a prospective intervention study addressing the effects of dietary sodium 
modulation and vitamin D receptor activator (VDRA) treatment on residual albuminuria in 
chronic kidney disease (CKD) patients on single-agent RAAS-blockade, as described in chapter 
2. We demonstrated that paricalcitol provided the lowest residual albuminuria during dietary 
sodium restriction, whereas during regular sodium intake paricalcitol had no effect on residual 
albuminuria. This finding highlights the clinical relevance of cross-talk between RAAS and vitamin 
D in a setting of renoprotective intervention, since the reduction of albuminuria is one of the 
key determinants of cardiorenal outcomes in CKD. Many studies have demonstrated that dietary 
sodium restriction potentiates the antiproteinuric efficacy of RAAS-blockade15-19, and apparently, 
this also applies to VDRA. 
Besides the interaction with vitamin D, the renoprotective effect of combined dietary sodium 
restriction and RAAS-blockade may be mediated by klotho. Klotho is considered a protective 
factor, and increasing soluble klotho levels is considered a target for cardiorenal therapy.20 
Surprisingly, in chapter 3, we discovered in a post-hoc analysis of a randomized controlled trial 
that the addition of dietary sodium restriction to background RAAS-blockade was accompanied 
by a small, albeit significant, reduction in serum klotho levels. We propose that this effect could 
be explained by a concomitant decline in renal function, by renal hypoxia or by increased RAAS 
S
SUMMARY, DISCUSSION AND FUTURE PERSPECTIVES
Proefschrift Charlotte Keyzer.indd   175 19-09-15   16:07
176
activation in patients on sodium restriction. An alternative explanation could be that technical 
limitations of the (IBL) klotho ELISA adversely influenced our results. Regardless of the underlying 
mechanism, our finding that dietary sodium restriction was accompanied by a reduction of serum 
klotho is in line with preclinical data.21 Conversely, both in preclinical21 and clinical22,23 studies, 
single-agent angiotensin receptor blockade (ARB) therapy increased klotho levels. In our study, 
on the other hand, the addition of an ARB to background ACE inhibitor (ACEi) did not increase 
klotho, particularly not during volume depletion. Our finding could at least in part be explained 
by the fact that in our study, ARB was added to background ACEi which was used throughout 
the study. This aspect of cross-talk between the RAAS and the vitamin D-FGF23-klotho axis 
could underlie the consistent observations from large clinical trials that dual RAAS-blockade 
does not confer additional long-term renoprotection despite albuminuria reduction.24-26 Of note, 
albuminuria was lowest in patients treated with low sodium and dual blockade, suggesting that 
deregulations in the vitamin D-FGF23-klotho axis, rather than albuminuria, would determine the 
long-term clinical outcome in the setting of dual RAAS blockade and volume depletion.
Part II – Clinical impact of cross-talk: novel clinical readouts and downstream factors
Deregulation of both the RAAS and the vitamin D-FGF23-klotho axis have been associated with 
adverse cardiovascular outcome. Progressive vascular calcification is a hallmark of CKD, and 
persists in the majority of renal transplant recipients27-29. Vascular calcification is the net result of 
several calcification-promoting and -inhibiting factors; therefore, a single factor cannot serve as a 
marker of overall calcification propensity. Interestingly, a novel assay able to quantify calcification 
propensity in serum has become available.30
In chapter 4 we quantified the serum calcification propensity in stable renal transplant 
recipients. Our main finding was that calcification propensity was associated with an increased 
risk of all-cause and cardiovascular mortality. These associations were independent of, and more 
strongly linked with outcomes than, established cardiovascular risk factors. Of interest, serum 
calcification propensity was also associated with graft failure in two independent cohorts. In 
theory, increased calcification propensity could lead to stiffness of the renal vasculature and 
intrarenal resistance. Another possible mechanism could be that mineralization propensity 
within the tubular system is related to the serum calcification propensity and to the risk of renal 
failure. This last hypothesis in known as the precipitation-calcification hypothesis, and is currently 
being re-considered in the field of renal failure progression.31,32
In order to translate this observation to clinically relevant targets for intervention, we set 
out to identify determinants of calcification propensity. In our cohort study serum magnesium, 
bicarbonate, albumin, and phosphate levels as well as the use of vitamin K antagonists were 
independently associated with calcification propensity
. 
These observations are in line with in 
vitro data demonstrating that phosphate has a direct accelerating effect, whereas magnesium, 
bicarbonate, albumin and vitamin K through γ-carboxyglutamic acid (Gla) protein have a direct 
delaying effect on calcification propensity.30,33-36
The inverse regulation of calcification propensity by vitamin K is mediated by endogenous 
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calcification inhibitors present in the vascular wall. One of the most prominent vitamin 
K-dependent calcification inhibitors is matrix Gla protein (MGP), requiring carboxylation by 
vitamin K.37 A recent preclinical study demonstrated a cause-effect relationship between 
decreased kidney function and vitamin K insufficiency through reduced endogenous vitamin 
K recycling.38 Furthermore, in preclinical setting angiotensin II exacerbated vascular calcification 
at least partially through inhibition of vascular MGP expression.39 As such, deregulated cross-
talk could negatively influence endogenous calcification inhibitors such as MGP through renal 
function loss and increased RAAS activation. Whether (deregulation of) the vitamin D-FGF23-
klotho axis directly influences (vitamin K-driven) calcification inhibitors is less clear, but studies 
on the bone phenotype of klotho-deficient (kl/kl) mice indeed suggest such effect40. In chapter 
5, we first studied the prevalence of vitamin K insufficiency, indicated by an increased (inactive) 
desphosphorylated-uncarboxylated MGP (dp-ucMGP) level, in renal transplant recipients. We 
found that the majority of renal transplant recipients are vitamin K deficient, probably at least in 
part due to dietary habits originating from the dialysis period, resulting in insufficient vitamin K 
intake.41 Chief dietary sources of vitamin K include green vegetables and cheeses, which usually 
are avoided by patients with end-stage kidney disease because of their potassium content. 
To provide more insight in the clinical implications of functional vitamin K insufficiency, we 
studied the association between (inactive) dp-ucMGP and clinical outcomes in renal transplant 
recipients. We found that high dp-ucMGP levels, indicative of functional vitamin K insufficiency, 
were independently associated with an increased risk of all-cause mortality in renal transplant 
recipients, in line with data in CKD patients.42 Given the potential to modulate vitamin K intake by 
dietary interventions and the availability of vitamin K supplements, vitamin K insufficiency seems 
an attractive target for therapeutic intervention. 
As discussed extensively above, vitamin D deficiency is considered one of the main clinically 
relevant consequences of deregulations in the vitamin D-FGF23-klotho axis, and also a major risk 
factor for adverse cardiorenal outcome. Thus, vitamin D status is also considered a clinically relevant 
readout of the deregulated cross-talk as outlined above. The definition of vitamin D deficiency 





is much more difficult to measure due to the approximately 1000-times lower plasma levels. 
Recent mass-spectrometry-based methods allow highly specific and sensitive quantification of 
1,25(OH)
2
D levels. Using this technique, in chapter 6, we compared the associations of both 
25(OH)D and 1,25(OH)
2
D, respectively, with clinical outcomes in renal transplant recipients. Our 
main finding was that we observed an inverse association between 25(OH)D, but not 1,25(OH)
2
D, 
and the risk of all-cause mortality, in line with earlier studies in the general population, CKD 
and hemodialysis patients.43-45 We hypothesize that the discordant associations of 25(OH)D and 
1,25(OH)
2
D with mortality is explained by autocrine/paracrine activation of 25(OH)D. The enzyme 
that converts 25(OH)D into 1,25(OH)
2
D, 1α-hydroxylase (CYP27B1), is not only expressed in renal 
tubular epithelial cells, but also in various extrarenal tissues. It is therefore conceivable that part 
of the circulating 25(OH)D is locally converted to 1,25(OH)
2
D, with subsequent local activation of 
vitamin D receptors.46 
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Our cohort study also revealed that a very low 25(OH)D level, i.e. <30 nmol/L, was associated with 
a more rapid annual decline in renal function in renal transplant recipients. The adverse renal 
effects of severe vitamin D deficiency might at least in part be mediated by loss of Wnt/β-catenin 
suppression. The Wnt/β-catenin pathway plays an important role in renal tissue responses to 
injury.47-51 Vitamin D modulates the Wnt/β-catenin pathway either directly through the VDR49 
or indirectly through downregulation of parathyroid hormone (PTH)52,53. Several endogenous 
extracellular antagonists of the Wnt pathway have been identified, including dickkopf-1 (Dkk-
1). Renal expression of Dkk-1 is upregulated by renal fibrosis49,50, and acts as an anti-fibrotic 
factor in different animal models47,54,55. In chapter 7, we studied the potential role of Dkk-1, thus 
being a potential novel factor downstream of the (deregulated) vitamin D-FGF23-klotho axis, in 
renal fibrosis and graft failure after kidney transplantation. Indeed, we found that serum Dkk-1 
is associated with renal fibrosis, and that a higher Dkk-1 level was associated with a reduced 
risk of graft failure. We hypothesize that Dkk-1 is upregulated following tissue injury as an anti-
fibrotic response, and that higher circulating Dkk-1 levels, possibly reflecting a more optimal 
anti-fibrotic response, may contribute to long-term protection against graft failure. Considering 
the associations of Dkk-1 and clinically relevant endpoints (both renal fibrosis and graft failure), 
Dkk-1 and related Wnt/β-catenin signaling could be an interesting target for novel anti-fibrotic 
therapies in the renal transplant population. Whether indeed VDRA therapy inhibits the Wnt/β-
catenin signaling and subsequently reduces the risk of graft failure after kidney transplantation, 
remains to be addressed.
Overall, in this part of the thesis we identified serum calcification propensity, vitamin K status, 
and plasma 25(OH)D as readouts relevant to study the clinical impact of deregulations in the 
vitamin D-FGF23-klotho axis. Indeed, each of these factors was associated with all-cause mortality 
in renal transplant recipients, independent of major confounders including renal function and 
established cardiovascular risk factors. Furthermore, we found that Dkk-1, an endogenous anti-
fibrotic factor downstream of (deregulations in) the vitamin D-FGF23-klotho axis, is not only 
connected with prevalent renal fibrosis but also with long-term renal outcomes. Future studies 
should focus on novel intervention strategies targeting these pathways, to address their efficacy 
to improve clinical outcomes in CKD patients and renal transplant recipients.
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DISCUSSION AND FUTURE PERSPECTIVES
This thesis addressed several levels of cross-talk between the RAAS and the vitamin D-FGF23-
klotho axis.1 Recent studies by us and others have enriched and extended the original cross-
talk paradigm by showing that klotho loss activates Wnt/β-catenin signaling56 and Wnt/β-
catenin subsequently activates the RAAS57. RAAS activation leads to klotho loss, thus causing an 
additional vicious cycle in CKD (Figure 1). In theory RAAS inhibition in combination with VDRA 
therapy could interrupt this vicious cycle. Indeed, the renoprotective effects of VDRA treatment 
may be partly mediated through increasing renal and soluble klotho levels58,59, and through 
suppressing Wnt/β-catenin signaling49.
Figure 1. Clinical implications of deregulations in the cross-talk between the RAAS and 
vitamin D-FGF23-klotho axis
In chronic renal disease, the renin-angiotensin-aldosterone system (RAAS) and vitamin 
D-FGF23-klotho axis are disturbed. Reduced activity of 1α-hydroxylase due to nephron loss 
and increased FGF23 leads to a reduction of 1,25(OH)
2
 vitamin D, which in turn activates 
the RAAS. The increased RAAS activity causes renal klotho loss and FGF23 resistance. 
Renal klotho loss activates Wnt/β-catenin signaling, a pathway that contributes to the 
development and progression of renal fibrosis, which in turn activates the RAAS. The factors 
identified as possible modes of intervention, as studied in this thesis, are indicated in grey.
Abbreviations: 1,25(OH)
2
D, 1,25-dihydroxy vitamin D
3
; 1α-OHase, 1α-hydroxylase; 25(OH)D, 25-hydroxyvitamin D
3
; FGF23, fibroblast growth factor 
23; Mg2+, magnesium; Na+, sodium; PO
4
3-, phosphate; RAASi, renin-angiotensin-aldosterone system inhibitor; VDRA, vitamin D receptor activator; 
VitK, vitamin K.  
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We further substantiated the paradigm by demonstrating that the renoprotective efficacy of 
combined VDRA treatment and RAAS-blockade is modulated by sodium intake. The results from 
our clinical trial are paralleled by a recent preclinical study in the adriamycin model of proteinuric 
nephropathy.60 In this model, the combination of VDRA and ACEi treatment reduced proteinuria 
during low (0.05%), but not high (2%) sodium diet. The better antiproteinuric effect during low 
sodium intake was accompanied by better protection against renal structural damage, shown 
by less renal inflammation, glomulerosclerosis and interstitial prefibrotic changes. Mechanistic 
studies suggest that the modulation of RAAS-blockade by sodium intake is related to the effects 
of sodium status on vascular and renal ACE activity,6,7,61,62 or on anti-inflammatory and anti-
fibrotic pathways14,63. 
Of interest, in both the preclinical and clinical setting, the renoprotective effects of VDRA 
treatment during RAAS-blockade were not accompanied by blood pressure reduction. It has 
been suggested that blood pressure reduction to very low levels accelerates progression of CKD, 
even when further reduction of albuminuria is achieved.64-66 Hence, especially for CKD patients 
with residual albuminuria and a relatively low blood pressure adjunct VDRA therapy could be 
attractive. 
In this thesis, we specifically studied the effect of vitamin D, RAAS-blockade and sodium 
intake on albuminuria. Whether the observed improvement in albuminuria translates into 
beneficial long-term outcomes remains to be addressed. The overall cardiorenal protective 
efficacy not only depends on the efficacy to reduce albuminuria, but also on possible adverse 
effects, particularly those related to calcium/phosphate metabolism. VDRA therapy was 
accompanied by an increase in serum phosphate and urinary calcium excretion. A recent 
prospective study showed that higher levels of 1,25(OH)2D were independently associated with 
an increased risk of incident nephrolithiasis.67 Higher serum phosphate levels may contribute to 
vascular calcification, by promoting vascular smooth muscle cell (VSMC) transformation towards 
an osteoblastic phenotype (as reviewed by Schlieper et al68). These possible adverse effects may 
counteract the beneficial cardiorenal effects of VDRA therapy, and therefore large randomized 
controlled clinical trials investigating the effect of vitamin D analogues on long-term clinical 
outcomes are needed. Considering our findings, VDRA treatment should be accompanied by 
moderate sodium restriction, to optimize its renoprotective effect.
Cardiovascular disease is the primary cause of death in patients with chronic kidney disease and 
renal transplant recipients. This excessive cardiovascular risk is driven by a progressive tendency 
to develop vascular calcification along with renal function loss. The study of (progressive) 
vascular calcification has been hampered by the fact that most techniques are restricted to 
assess prevalent calcifications. Recently, a novel test has become available that quantifies 
calcification propensity in serum.30 Calcification propensity, which measures the (im)balance 
between calcification promoters and inhibitors, might be used as a screening test for the early 
detection of patients at high risk of cardiovascular complications. Furthermore, it is tempting to 
speculate that calcification propensity may guide treatment to prevention or treat cardiovascular 
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complications in renal patients. In this thesis we identified multiple determinants of serum 
calcification propensity, which are either directly or indirectly related to deregulations in the 
cross-talk between the vitamin D-FGF23-klotho axis and the RAAS (Figure 1). 
First of all, we found that serum phosphate was the strongest independent determinant 
of calcification propensity. Reducing dietary phosphate absorption by dietary phosphate 
restriction, calcium-free phosphate binders and/or sodium-dependent phosphate co-
transporter 2b [NPT2b] blockade seems to lower both serum phosphate69,70 and FGF23 levels,71,72 
and could thus improve calcification propensity. Of note, the CKD Optimal Management with 
BInders and NicotinamidE (COMBINE) study is currently investigating whether the combination 
of nicotinamide (vitamin B3, which reduces intestinal NPT2b expression) and lanthanum 
carbonate (a calcium-free phosphate binder) during dietary phosphate restriction reduces 
serum phosphate and FGF23.73 
Second, calcimimetics (i.e. cinacalcet) might prevent the progression of cardiovascular 
calcifications and improve calcification propensity. In a preclinical study either cinacalcet or 
parathyroidectomy reduced vascular calcifications in uremic rats, indicating that the possible 
mechanism of action is suppression of PTH production.74 A recently published secondary analysis 
of the Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) trial suggested 
that lowering FGF23 by cinacalcet therapy reduces the risk of cardiovascular events and death 
among hemodialysis patients with secondary hyperparathyroidism.75 
Third, targeting serum magnesium could improve calcification propensity. Multiple 
observational studies have identified low serum magnesium as a risk factor of faster decline of 
kidney function, cardiovascular morbidity and all-cause mortality in CKD.76,77 Furthermore, a cohort 
study among renal transplant recipients identified low serum magnesium as an independent 
predictor of vascular stiffness.78 Of interest, recently it was suggested that magnesium could 
be protective against the harmful effects of phosphate on the kidney.79 Large randomized trials 
are warranted to assess the benefits of magnesium correction or supplementation on long-
term outcomes in CKD and renal transplantation. Considering the possible beneficial effect 
of magnesium on calcification, it could be relevant to reconsider the risk-benefit balance of 
pharmacotherapy that negatively influences serum magnesium such as proton-pomp inhibitors, 
loop diuretics and calcineurin inhibitors in CKD and renal transplantation. 
Finally, serum calcification propensity may be improved by vitamin K. Besides its role in 
coagulation, vitamin K is required for activation of matrix Gla protein (MGP), a powerful vascular 
calcification inhibitor. Recently it was shown in the preclinical setting that uremia per se can 
interfere with the vitamin K recycling system38, contributing to vitamin K deficiency in CKD and 
renal transplantation. Circulating inactive MGP, including desphosphorylated-uncarboxylated 
MGP, levels formed as a result of vitamin K deficiency, are associated with cardiovascular disease 
and overall survival in CKD42 and renal transplantation80. The effect of vitamin K supplementation 
in hemodialysis patients on vascular calcification, cardiovascular morbidity and mortality is 
currently being studied in the VitaVask study.81 In addition, dietary counseling may be an attractive 
adjunct therapy, particularly in the renal transplant population in which patients often maintain 
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vitamin K-poor dietary habits originating from the dialysis period. On the other hand, the use of 
vitamin K antagonists has been associated with increased progression of vascular calcification. 
In experimental setting, the administration of vitamin K antagonist resulted in severe vascular 
calcification, which was (partially) reversible by high vitamin K intake.82 Furthermore, multiple 
human studies have described the disadvantageous effect of vitamin K antagonists on vascular 
calcification (as reviewed by Chatrou et al83). Currently a randomized controlled trial is investigating 
the effect of vitamin K antagonist versus non-vitamin K antagonist oral anticoagulants in patients 
with atrial fibrillation and/or pulmonary embolism on the development and progression of 
vascular calcification (ClinicalTrial.gov No. NCT02066662). Considering that both CKD and renal 
transplantation patients are prone to vascular calcification, future studies should focus on the 
use of non-vitamin K antagonist such as dabigatran for oral anticoagulation in these patients. Of 
interest, a recent preplanned interim analysis of the Reversal Effects of Idarucizumab on Active 
Dabigatran (RE-VERSE AD) study showed that idarucizumab, a monoclonal antibody fragment, 
can reverse the anticoagulant effect of dabigatran in emergency situations within minutes.84
In conclusion, the complex interactions between (deregulations in) the RAAS and the vitamin 
D-FGF23-klotho axis drive progressive renal function loss and cardiovascular complications, 
and at least in part explain why targeting the classical cardiorenal risk factors is unsatisfying. 
Considering the cross-talk between these different pathways, future studies should focus on 
simultaneous intervention in multiple pathways, using both dietary (high intake of magnesium, 
vitamin D and vitamin K, and moderate sodium restriction) and pharmacological (RAASi, VDRA, 
calcimimetics) approaches. Individual titration of parameters determining serum calcification 
propensity should pave the way towards personalized medicine, aiming to reverse vascular 
calcification propensity and reduce cardiorenal risk in renal patients.
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